ProstaLund AB (publ) has signed an exclusive distribution agreement with Distribuzione Bio Medicali Italia DBI srl. The agreement is expected to generate revenues of at least SEK 1.5 million during the first two years of the agreement period. With the help of ProstaLund's products, DBI's existing customers can now be offered a holistic concept that means that the treatments can be performed under local anesthesia and thereby save resources.

During the fall, ProstaLund introduced the Schelin Catheter and CoreFlow – Soft Stent at a handful of clinics in Italy with very good results. The partnership with DBI enables the introduction to be significantly accelerated.